Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:43:50 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:XOMA - XOMA ROYALTY CORPORATION EFFE - https://www.xoma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XOMA - Q0.622.95·25.480.224.86-0.06-0.2401.09,8373,90825.41  26.29  24.7739.92  18.4019:44:34Jan 1215 min RT 2¢

Recent Trades - Last 10 of 3908
Time ETExPriceChangeVolume
19:44:34Q24.8724-0.047612
19:44:14Q24.85-0.0711
19:43:38Q24.8756-0.04445
18:56:05Q25.000.08100
16:20:00Q24.86-0.0653
16:10:05Q24.86-0.061
16:04:16Q24.86-0.061
16:04:16Q24.86-0.061
16:04:06Q24.86-0.061
16:01:36Q24.86-0.0672

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 07:30U:XOMANews ReleaseXOMA Royalty Announces CFO Transition
2025-12-30 07:30U:XOMANews ReleaseXOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
2025-12-22 07:30U:XOMANews ReleaseXOMA Royalty Declares Quarterly Preferred Stock Dividends
2025-12-15 17:00U:XOMANews ReleaseXOMA Royalty Enters into Agreement to Acquire Generation Bio
2025-12-05 09:00U:XOMANews ReleaseXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
2025-12-05 07:45U:XOMANews ReleaseMural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
2025-11-26 09:00U:XOMANews ReleaseMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
2025-11-21 07:45U:XOMANews ReleaseXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
2025-11-12 07:30U:XOMANews ReleaseXOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
2025-11-10 16:09U:XOMANews ReleaseLAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
2025-10-24 16:26U:XOMANews ReleaseMural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
2025-10-17 11:45U:XOMANews ReleaseXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
2025-10-02 16:43U:XOMANews ReleaseXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
2025-09-24 06:00U:XOMANews ReleaseESSA Pharma Inc. Amends Agreement with XenoTherapeutics
2025-09-22 07:30U:XOMANews ReleaseXOMA Royalty Declares Quarterly Preferred Stock Dividends
2025-09-17 09:00U:XOMANews ReleaseXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
2025-09-03 07:30U:XOMANews ReleaseXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
2025-08-20 08:49U:XOMANews ReleaseMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share